BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Qelbree (viloxazine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Qelbree (viloxazine)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02736656-10826@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Qelbree (viloxazine): Phase 3 readout est. (NCT02736656)
DESCRIPTION:Qelbree (viloxazine)\, phase 3\, Attention Deficit Hyperactivit
 y Disorder.\nStudy: Open-label Study to Evaluate Long-term Safety and Effi
 cacy of SPN-812 (Viloxazine Extended-release Capsule)\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/viloxazine#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02736656
URL:https://assetmemo.bio/drug/viloxazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07678827-10826@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Qelbree (viloxazine): Phase 3 readout est. (NCT07678827)
DESCRIPTION:Qelbree (viloxazine)\, phase 3\, Attention Deficit Hyperactivit
 y Disorder.\nStudy: A Phase 3 Study of Viloxazine ER Capsules in Korean Ch
 ildren and Adolescents With ADHD\nEstimated primary completion: September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/viloxazine#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07678827
URL:https://assetmemo.bio/drug/viloxazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04781140-10826@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Qelbree (viloxazine): Phase 4 readout est. (NCT04781140)
DESCRIPTION:Qelbree (viloxazine)\, phase 4\, Attention Deficit Hyperactivit
 y Disorder.\nStudy: Evaluation of SPN-812 (Viloxazine Extended-release Cap
 sule) in Preschool-age Children With ADHD\nEstimated primary completion: J
 anuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/viloxazi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4781140
URL:https://assetmemo.bio/drug/viloxazine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
